3.52 (-%)
As of Nov 04, 2024
Source:
Marker Therapeutics, Inc. is a clinical-stage immuno-oncology company specializing in the development and commercialization of novel T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications. We developed our lead product candidates from our multiTAA-specific T cell technology, which is based on the manufacture of non-engineered, tumor-specific T cells that recognize multiple tumor associated antigens, or TAAs.
Country | United States |
Headquarters | houston, texas |
Phone Number | (713) 400-6400 |
Industry | manufacturing |
CEO | Peter Hoang |
Website | www.markertherapeutics.com |